-

05:02:37 AM

QGEN Stock News

QGEN - Qiagen NV

05/03/23 4:05 PM

NYSE : QGEN

covid-19

QIAGEN exceeds outlook for Q1 2023 with 12% CER sales growth in non-COVID product portfolio

Q1 2023: Net sales of $485 million (-23% at actual rates, -20% at constant exchange rates, CER); diluted EPS of $0.37 and adjusted diluted EPS of $0.51 // Net sales at CER of $502 million ahead of outlook for at least $490 million CER and adjusted diluted EPS of $0.52 CER ahead of outlook for at

RHEA-AI

neutral

05/03/23 5:30 AM

NYSE : QGEN

QIAGEN welcomes U.S. Preventive Services Task Force reaffirmation for latent TB screening in populations at increased risk

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it welcomed the U.S. Preventive Services Task Force (USPSTF) reaffirming a previously issued recommendation for latent tuberculosis infection

RHEA-AI

neutral

04/24/23 4:05 PM

NYSE : QGEN

QIAGEN launches QIAstat-Dx in Japan with respiratory panel for syndromic testing

Japan to become the latest of more than 100 countries where QIAstat-Dx is available for molecular testing in diagnosing over 20 respiratory diseases from one patient sample // Generates actionable results in about one hour based on PCR technology, unique ability to provide Ct values and easy access

RHEA-AI

very positive

04/20/23 4:05 PM

NYSE : QGEN

QIAGEN announces expansion of Supervisory Board

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Steve Rusckowski, an internationally recognized

RHEA-AI

neutral

04/14/23 6:00 AM

NYSE : QGEN

QIAGEN showcases latest technologies to advance cancer research at AACR Annual Meeting 2023

Launch of cell-free DNA (cfDNA) next-generation sequencing kits to test liquid biopsies // Study to demonstrate QIAGEN’s expertise in detecting disease-relevant cfDNA mutations // New pan-cancer panels for digital PCR platform QIAcuity to be launched in fall 2023 Venlo, the Netherlands, April 14,

RHEA-AI

positive

03/29/23 8:00 AM

Nasdaq : QGEN

QIAGEN’s QIAxcel Connect wins Red Dot design award

International design competition recognizes high-resolution DNA or RNA capillary electrophoresis instrument // QIAxcel marks the fourth QIAGEN instrument to receive Red Dot award, highlights strategy of upgrading portfolio to add new features – in particular wireless connectivity // QIAxcel Connect

RHEA-AI

neutral

03/27/23 8:00 AM

Nasdaq : QGEN

QIAGEN receives approval for its net-zero carbon emissions target by Science Based Targets initiative (SBTi)

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its emissions reduction targets have been validated by the Science Based

RHEA-AI

positive

03/13/23 8:01 AM

NYSE : QGEN

QIAGEN Announces Form 20-F Annual Report Filing for 2022 Results

QIAGEN N.V. announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20- F, for the year ended December 31, 2022, with the U.S. Securities and Exchange Commission. QIAGEN will provide printed copies of the 2022 Annual Report to shareholders free of charge upon request.

RHEA-AI

neutral

03/09/23 1:30 AM

NYSE : QGEN

partnership

QIAGEN and Servier Partner to Develop Companion Diagnostic for Acute Myeloid Leukemia (AML) Therapy Drug

QIAGEN to develop PCR test to detect isocitrate dehydrogenase-1 mutations in AML patients to be used with Servier’ s marketed and investigational targeted treatment Test for blood and bone marrow samples to run on QIAGEN Rotor-Gene Q device QIAGEN now working with more than 30 companies to develop and commercialize companion diagnostics.

RHEA-AI

positive

03/01/23 9:00 AM

Nasdaq, NYSE : SOPH, QGEN

partnership

SOPHiA GENETICS and QIAGEN Forge Partnership to Combine Strengths in Next-generation Sequencing

SOPHiA GENETICS, a cloud-native software company in the healthcare space, today announced a new partnership with QIAGEN N.V. that will pair QIAseq reagent technology with the SOPHiA DDM™ platform to enhance tumor analysis through next-generation sequencing. To get there, we are partnering with reagent manufacturers so that our...

RHEA-AI

very positive

1 2 3 4 5 6 7 8 9 10 Next

QGEN Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websiteqiagen.com
CeoThierry Bernard
Security nameQiagen NV
Issue typecs
SectorManufacturing
Sic code2836
Employees6178
Tags
- Health Technology
- Medical Specialties
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
AddressHulsterweg 82
StateLimburg
CityVenlo
Zip5912 PL
CountryNetherlands
Phone31773556600

About Qiagen NV

qiagen is the leading global provider of sample to insight solutions to transform biological materials into valuable molecular insights. qiagen sample technologies isolate and process dna, rna and proteins from blood, tissue and other materials. assay technologies make these biomolecules visible and ready for analysis. bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. automation solutions tie these together in seamless and cost-effective molecular testing workflows. qiagen provides these workflows to more than 500,000 customers around the world in molecular diagnostics (human healthcare), applied testing (forensics, veterinary testing and food safety), pharma (pharmaceutical and biotechnology companies) and academia (life sciences research). as of june 30, 2015, qiagen employed approximately 4,400 people in over 35 locations worldwide. further information can be found at http://www.qiagen.com.